Instructions for Authors
Please note that publication in this open-access journal is free of charge to readers.
Changes to submission policy
JVE is an open-access (OA) journal, which has been free for authors to contribute their work and for readers since its inception. JVE provides a valuable resource to scientists, researchers, healthcare professionals, and the public globally.
Authors’ work is reviewed, edited and made available on the JVE website and, as an open-access journal that meets the selection criteria for NLM, is in PubMed Central and indexed by PubMed. This provides a highly esteemed platform for authors. After 5 years of publishing OA articles of high academic standard completely free of charge, the Journal needs your help to continue its work and raise the funding to make it possible.
We want to make sure that JVE can remain free for authors from developing countries (see full list below) and for our readers.
JVE offers authors full open access to have their article immediately freely available to everyone, without the need for a subscription. To cover the cost of publishing OA, authors pay an article publication charge (APC). The APC for the journal can be found at the end of the Instructions for Authors.
Some organisations pay APCs for their authors and your institution or funder may be able to help with open access APCs.
To ensure that editorial decisions are never influenced by ability to pay and to ensure we maintain the high academic standard of the research published, we offer discounted rates or automatic waivers to authors from countries listed below.
Authors based in the following countries are eligible to receive an automatic waiver for APCs when publishing in JVE. Authors are requested to apply for this at the time of manuscript submission:
Afghanistan, Albania, Angola, Bangladesh, Belarus, Belize, Benin, Bhutan, Bosnia and Herzegovina, Burkina Faso, Cabo Verde, Cambodia, Cameroon, Central African Republic, Comoros, Côte d'Ivoire, Cuba, Democratic People's Republic of Korea, Democratic Republic of Congo, Djibouti, Equatorial Guinea, Eritrea, Ethiopia, Gambia Ghana, Guinea, Guinea-Bissau, Haiti, Iran, Iraq, Kenya, Kiribati, Kosovo Kyrgyzstan, Lao People's Republic, Lesotho, Liberia, The former Yugoslav Republic of Macedonia, Madagascar, Malawi, Mali, Marshall Islands, Mauritania, Micronesia (Federated States of), Montenegro, Mozambique, Myanmar, Nepal, Nicaragua, Niger, Papua New Guinea, Republic of Moldova, Rwanda, Samoa, Sao Tome and Principe, Senegal, Serbia, Sierra Leone, Solomon Islands, Somalia, South Sudan, Swaziland, Syrian Arab republic, Tajikistan, Timor-Leste, Togo, Tokelau, Tonga, Tunisia, Tuvalu, Uganda, United Republic of Tanzania, Vanuatu, Yemen, Zambia, Zimbabwe.
Authors based in the following countries are eligible to receive a 50% discount on APCs when publishing in JVE. Authors are requested to apply for this at the time of manuscript submission.
Algeria, • Antigua and Barbuda • Armenia • Bolivia • Botswana • Cook Islands • Dominica • Egypt • El Salvador • Fiji • Gabon • Georgia • Grenada • Guatemala • Guyana • Honduras • Jamaica • Jordan • Libya • Maldives • Mauritius • Mongolia • Morocco • Namibia • Nauru • Nigeria • Niue • Pakistan • Palau • Paraguay • Saint Helena • Saint Kitts and Nevis • Saint Lucia • Saint Vincent and the Grenadines • Seychelles • Sri Lanka • Suriname • Ukraine • Uzbekistan • Viet Nam • West Bank and Gaza Strip
Please look through the instructions for authors below, and then simply follow the link from the 'Continue' button to the Journal of Virus Eradication Editorial Manager manuscript submission system and follow the instructions. The manuscript itself should be submitted as a rich text (RTF format) or Word document, with any tables or figures included in the main text document.
During the submission process, the submitting author will be asked whether the work has been, or is being considered for publication elsewhere and will be required to state on behalf of all the authors that the work meets all relevant ethical guidelines and legal requirements. Please note that the journal seeks to follow the Code of Conduct and Best Practice Guidelines for Journal Editors
Please note, any misconduct by authors in reporting their data, e.g. falsification of results, will lead to rejection of their manuscript and other consequences. The Editors will follow the Committee on Publication Ethic's Code of Conduct flowcharts and implement that advice when faced with cases of suspected misconduct.
The content of the Journal is the work of the individual authors and is under the sole control of our independent and eminent Editorial Board. Contributions to the journal are judged on their own merits, regardless of funding, author affiliations or author relationships. While our open-access journal is free for authors and readers, and is funded by donations, sponsors and paid advertisements, no financial supporter of the journal has any input into its content. This is entirely under the control of the Editorial Board.
Conflicts of interest and editors, authors and peer reviewers
To avoid actual or perceived conflicts of interest, editors do not take part in editorial decisions should they have competing interests related to an article under consideration. Authors are required to disclose financial and personal relationships that might bias or be seen to bias their work when submitting a manuscript. Peer reviewers are also asked to disclose whether they have conflicts of interest that could bias their review and are asked to withdraw should there be any conflict.
Human and animal rights policy
The journal requires that all experimentation on human and animal subjects is conducted according to the ethical standards of the author's institution and relevant national and international guidelines. All experimental work on human or animal subjects must be approved by the institution's ethics committee. If there is any doubt, the editors will request an explanation for the approach and proof of ethics committee approval.
For all research involving human subjects, informed consent to participate in the study must be obtained from participants (or their parent or guardian in the case of children under 16) and a statement to this effect should appear when submitting the manuscript.
In addition, the journal will not publish any material that could potentially identify an individual who has participated in a study unless the individual has specifically given written consent, copies of which should be submitted with the manuscript.
All submitted manuscripts will be acknowledged by the Editor.
Please contact us if you need any further assistance.
The Journal of Virus Eradication is an open-access journal and authors retain their copyright. Authors grant the publisher, Mediscript Ltd, a licence to publish the article and identify itself as the original publisher. During the submission process, the submitting authors will choose, on behalf of all authors of the work, one of the following Creative Commons License Open Access Agreements (OAA):
Creative Commons Attribution Non-Commercial License OAA (CC BY-NC)
Creative Commons Attribution Non-Commercial - NoDerivs License OAA (CC BY-NC-ND)
A CC BY-NC licence permits non-commercial use of your work by others provided your original work is cited properly.
A CC BY-NC-ND licence permits non-commercial use of your work by others provided your original work is cited properly and also remains unchanged.
For more information about creative commons licences, please see: https://www.creativecommons.org
If a different creative commons licence is required, please contact us.
The Journal publishes a variety of papers: Original research, Reviews, Viewpoints, Conference reports, Letters to the editor and Case studies.
Original research or Reviews have an abstract, main text up to 3,500 words, a maximum of six tables or figures and 20–50 references.
A Viewpoint would typically have an abstract, main text up to 2,000 words, a maximum of two tables or figures and up to 20 references.
A Letter would typically be up to 500 words, optionally have one table or figure and up to five references.
Please include the following for all article types:
- A concise article title
- Initials or first names and family names of each of the authors (with superscript numbers to indicate affiliations
- Affiliations (department, institution, city, country)
- A shortened version of the title (50 characters maximum) to be used as the running head
- The name and full postal and email address of corresponding author
Please include an abstract for all article types except Conference reports, Case reports and Letters to the editorLength:up to 250 words
For original research only, please divide into sections entitled Objectives, Methods, Results and Conclusions
- Include a list of up to five keywords
The abstract should describe the content of the paper and the important conclusions accurately, couched in terms that will be understood by most readers of the Journal.
For original research, please divide the text into Introduction, Methods, Results, Discussion and Acknowledgements sections, with subheadings as necessary (see below).There are no specific structure requirements for other article types.
In terms of writing style, please avoid abbreviations (except those commonly understood), long sentences and many juxtaposed numbers in sentences. In addition, please use generic names for drugs or any molecules used. Measurements should be in SI units and use a solidus (/) where necessary rather than indices.
These should be in the Vancouver style, i.e. numbered throughout the text in consecutive order using Arabic numerals in parentheses. The references should be listed in numerical order at the end of the paper using the following styles. List all authors when six or fewer and list the first three followed by et al. when there are more than six. Unpublished work should only be cited in the text. Only references genuinely in press should be listed in the reference list. We recommend the use of a tool such as EndNote or Mendeley for reference management and formatting.
Examples of referencesVanderpump MPJ. The epidemiology of thyroid disease. In: Braverman LE, Utiger RD, eds. Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text. Philadelphia, PA: Lippincott Williams and Wilkins, 2005; pp 5–9.
Ananworanich J, Sacdalan CP, Pinyakorn S et al. Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection. J Virus Erad 2016; 2: 43–48.
Sissoko D, Duraffour S, Kolie J et al. Dynamics of
Ebola virus clearance in semen in Guinea. Conference on Retroviruses and
Opportunistic Infections. February 2016. Boston, MA, USA. Abstract 75LB.
Tables, Figures and Illustrations
Tables should be numbered consecutively with Arabic numerals with a fully informative caption as a heading. Column headings should be brief, with units of measurement in parentheses. Vertical lines should not be used to separate columns. Electronic tables should be provided in an editable format (.rtf or .doc). All illustrations (including photographs) are classified as figures and should also be numbered consecutively. Please include all tables at the end of the main text.
Authors should submit artwork within the body of the main text. Figures will be assessed for quality of reproduction in online formats. Please note that, if necessary, figures may be re-lettered or re-drawn to follow house style.
Please advise us if you wish to provide extensive supplementary material (Appendices) beyond the specified word count so that suggestions on how best to publish this may be discussed.
Permission for using previously published artwork
If you wish to use previously published artwork, it is the authors' responsibility to obtain and provide proof of permission from the copyright holder (usually the publisher or author). Please send copies of the grant of permission with your manuscript.
Additional instructions for Original research
Please include all information necessary for other suitably skilled researchers to repeat the study. If the protocol used is well established, please cite the published work that describes it in detail. Entirely new methods can be fully described in an Appendix with enough detail in the text for the method to be understood. Please include reasons for your chosen methodology. Appendices over 500 words in total will no longer be published; authors are advised to provide a link to a website where supplementary material may be viewed or to make the material available to readers on request.
Please also include a statement on any ethical considerations in your research, including the consent procedure followed.
This section should consist of the results of the research. When giving statistical results, please report confidence intervals and levels of significance where appropriate.
Please discuss your main findings within the context of current knowledge. If applicable, any study limitations and how they may influence the results can be discussed.
Apart from any brief acknowledgements that you may wish to include, please provide concise information for the following sections.
Declaration of interests
Please list any competing interests for each author. Please state if there are no declarations to be made.
Please list the source(s) of funding for the research.
All Original research submitted to the journal is peer-reviewed.
Invited reviews, Viewpoints, Conference reports, Letters to the editors
All invited Reviews, Viewpoints, Conference reports and Letters to the editors are reviewed by the Editors before acceptance for publication.
Reviews submitted to the Journal, but not specifically invited
Reviews submitted to the journal that have not been specifically invited are considered by the Editors in the first instance. The Editors decide whether to review the submission themselves or invite external peer-review.
Authors are requested to suggest two potential reviewers of their work when they submit their manuscripts. The Editors may agree with these suggestions or may decide to ask others to review the work.
In the first instance, reviewers are invited to review within the manuscript within 2 weeks. Two or three reviews are sought. The Editors assess the reviewers' recommendations and reports, and make their final decision. This is then sent, along with the report, to the authors.
Articles submitted to the Journal remain confidential throughout the review process. Reviewers' identities are also confidential unless the reviewer specifically wishes to be identified.
Once an article has been accepted for publication, and any revisions have been made, the manuscript is copyedited and then typeset. However, if there are many queries from the copyeditor, the document may be returned to the author for the queries to be answered.
Once typeset, pdf proofs are sent by email to the corresponding author. The proofs must be returned to the Editorial Office within 3 days of receipt. Only typographical errors and other essential small changes can be made at this stage. Major alterations to the text cannot be accepted.
Please contact the Editorial Office if you would like to purchase printed offprints.
Author Publication Charges
£1500 (US$1950; €1770)
Discounted APC (50%)
£750 (US$975; €885)
For more information about APC and how to pay, please see here
To start the submission process click the continue button below. Please note that on clicking the 'Continue' button, you will be taken to the Journal of Virus Eradication Editorial Manager website.